{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:44:28Z","timestamp":1787021068588,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012547","name":"Natural Science Foundation of Guangxi Zhuang Autonomous Region","doi-asserted-by":"publisher","award":["2024GXNSFAA010107"],"award-info":[{"award-number":["2024GXNSFAA010107"]}],"id":[{"id":"10.13039\/100012547","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012547","name":"Natural Science Foundation of Guangxi Zhuang Autonomous Region","doi-asserted-by":"publisher","award":["2023GXNSFBA026106"],"award-info":[{"award-number":["2023GXNSFBA026106"]}],"id":[{"id":"10.13039\/100012547","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Epileptologica"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Sialidosis is an autosomal recessive hereditary disease characterized by the mutation of neuraminidase-1 (\n                      <jats:italic>NEU1<\/jats:italic>\n                      ) gene, resulting in decreased activity of \u03b1-N-acetylneuraminidase. This leads to metabolic abnormalities in various organs. Sialidosis is classified into two distinct clinical phenotypes, type I and type II, based on the age of onset and severity of clinical manifestations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      Here, we report a case involving a patient and his two sisters, all of whom showed seizures and ataxia during adolescence, with progressively worsening symptoms. Prior to admission, none of the patients had received a systemic diagnosis or treatment. The whole exome sequencing identified a homozygous\n                      <jats:italic>NEU1<\/jats:italic>\n                      mutation (NM_000434.3:c.544A\u2009&gt;\u2009G [p.Ser182Gly]) in all three siblings. Their parents and children, who were asymptomatic, were found to be heterozygous carriers. The three patients were ultimately diagnosed with type I sialidosis and treated with antiseizure medications, but they continued to experience recurrent seizures.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case report enhances our understanding of sialidosis, particularly in patients presenting with seizures and ataxia. Furthermore, the gene sequencing is a crucial tool for confirming the diagnosis of sialidosis and provides a valuable approach for genetic counseling in affected families.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42494-025-00225-3","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T04:32:36Z","timestamp":1749011556000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Type I Sialidosis in a Chinese family: a case report and literature review"],"prefix":"10.1186","volume":"7","author":[{"given":"Xia","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyou","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZuFang","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liling","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binglin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"225_CR1","doi-asserted-by":"crossref","unstructured":"S Franceschetti, L Canafoglia. Sialidoses. Epileptic Disord. 2016;18(S2)89\u201393.","DOI":"10.1684\/epd.2016.0845"},{"issue":"4","key":"225_CR2","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s10719-018-9837-4","volume":"35","author":"AV Pshezhetsky","year":"2018","unstructured":"Pshezhetsky AV, Ashmarina M. Keeping it trim: roles of neuraminidases in CNS function. Glycoconj J. 2018;35(4):375\u201386.","journal-title":"Glycoconj J"},{"issue":"11","key":"225_CR3","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s00018-013-1538-3","volume":"71","author":"EJ Bonten","year":"2014","unstructured":"Bonten EJ, Annunziata I, d\u2019Azzo A. Lysosomal multienzyme complex: pros and cons of working together. Cellular and molecular life sciences\u202f: CMLS. 2014;71(11):2017\u201332.","journal-title":"Cellular and molecular life sciences : CMLS"},{"key":"225_CR4","doi-asserted-by":"publisher","first-page":"100561","DOI":"10.1016\/j.ymgmr.2019.100561","volume":"22","author":"V Arora","year":"2020","unstructured":"Arora V, Setia N, Dalal A, Vanaja MC, Gupta D, Razdan T, et al. Sialidosis type II: Expansion of phenotypic spectrum and identification of a common mutation in seven patients. Molecular genetics and metabolism reports. 2020;22:100561.","journal-title":"Molecular genetics and metabolism reports"},{"issue":"5","key":"225_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1517\/21678707.2015.1025746","volume":"3","author":"A d'Azzo","year":"2015","unstructured":"d\u2019Azzo A, Machado E, Annunziata I. Pathogenesis, Emerging therapeutic targets and Treatment in Sialidosis. Expert Opin Orphan Drugs. 2015;3(5):491\u2013504.","journal-title":"Expert Opin Orphan Drugs"},{"issue":"18","key":"225_CR6","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1093\/hmg\/9.18.2715","volume":"9","author":"EJ Bonten","year":"2000","unstructured":"Bonten EJ, Arts WF, Beck M, Covanis A, Donati MA, Parini R, et al. Novel mutations in lysosomal neuraminidase identify functional domains and determine clinical severity in sialidosis. Hum Mol Genet. 2000;9(18):2715\u201325.","journal-title":"Hum Mol Genet"},{"issue":"4","key":"225_CR7","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1159\/000515081","volume":"12","author":"EA Flores-Contreras","year":"2021","unstructured":"Flores-Contreras EA, Garcia-Ortiz JE, Robles-Espinoza CD, Zomosa-Signoret V, Becerra-Solano LE, Vidaltamayo R, et al. Clinical Exome Sequencing Enables Congenital Sialidosis Type II Diagnosis in Two Siblings Presenting with Unreported Clinical Features from a Rare Homozygous Sequence Variant p.(Tyr370Cys) in NEU1. Mol Syndromol. 2021;12(4):250\u20137.","journal-title":"Mol Syndromol."},{"key":"225_CR8","doi-asserted-by":"publisher","first-page":"100832","DOI":"10.1016\/j.ymgmr.2021.100832","volume":"30","author":"AO Gupta","year":"2022","unstructured":"Gupta AO, Patterson MC, Wood T, Eisengart JB, Orchard PJ, Lund TC. Hematopoietic cell transplantation for sialidosis type I. Molecular genetics and metabolism reports. 2022;30:100832.","journal-title":"Molecular genetics and metabolism reports"},{"issue":"2","key":"225_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ymgme.2019.09.005","volume":"129","author":"A Caciotti","year":"2020","unstructured":"Caciotti A, Melani F, Tonin R, Cellai L, Catarzi S, Procopio E, et al. Type I sialidosis, a normosomatic lysosomal disease, in the differential diagnosis of late-onset ataxia and myoclonus: An overview. Mol Genet Metab. 2020;129(2):47\u201358.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"225_CR10","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s12311-019-1005-2","volume":"18","author":"JH Ahn","year":"2019","unstructured":"Ahn JH, Kim AR, Lee C, Kim NKD, Kim NS, Park WY, et al. Type 1 Sialidosis Patient With a Novel Deletion Mutation in the NEU1 Gene: Case Report and Literature Review. Cerebellum. 2019;18(3):659\u201364.","journal-title":"Cerebellum"},{"issue":"1","key":"225_CR11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2169\/internalmedicine.52.8901","volume":"52","author":"Y Sekijima","year":"2013","unstructured":"Sekijima Y, Nakamura K, Kishida D, Narita A, Adachi K, Ohno K, et al. Clinical and serial MRI findings of a sialidosis type I patient with a novel missense mutation in the NEU1 gene. Intern Med. 2013;52(1):119\u201324.","journal-title":"Intern Med"},{"issue":"2","key":"225_CR12","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1159\/000008141","volume":"43","author":"S Palmeri","year":"2000","unstructured":"Palmeri S, Villanova M, Malandrini A, van Diggelen OP, Huijmans JG, Ceuterick C, et al. Type I sialidosis: a clinical, biochemical and neuroradiological study. Eur Neurol. 2000;43(2):88\u201394.","journal-title":"Eur Neurol"},{"issue":"1","key":"225_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13073-022-01026-w","volume":"14","author":"S Marwaha","year":"2022","unstructured":"Marwaha S, Knowles JW, Ashley EA. A guide for the diagnosis of rare and undiagnosed disease: beyond the exome. Genome medicine. 2022;14(1):23.","journal-title":"Genome medicine"},{"issue":"7814","key":"225_CR14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41586-020-2434-2","volume":"583","author":"E Turro","year":"2020","unstructured":"Turro E, Astle WJ, Megy K, Graf S, Greene D, Shamardina O, et al. Whole-genome sequencing of patients with rare diseases in a national health system. Nature. 2020;583(7814):96\u2013102.","journal-title":"Nature"},{"issue":"6","key":"225_CR15","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/acn3.51058","volume":"7","author":"RJ Lv","year":"2020","unstructured":"Lv RJ, Li TR, Zhang YD, Shao XQ, Wang Q, Jin LR. Clinical and genetic characteristics of type I sialidosis patients in mainland China. Ann Clin Transl Neurol. 2020;7(6):911\u201323.","journal-title":"Ann Clin Transl Neurol"},{"key":"225_CR16","doi-asserted-by":"publisher","first-page":"105279","DOI":"10.1016\/j.nbd.2021.105279","volume":"152","author":"H Odaka","year":"2021","unstructured":"Odaka H, Numakawa T, Soga M, Kido J, Matsumoto S, Kajihara R, et al. An iPSC-based neural model of sialidosis uncovers glycolytic impairment-causing presynaptic dysfunction and deregulation of Ca(2+) dynamics. Neurobiol Dis. 2021;152:105279.","journal-title":"Neurobiol Dis"},{"issue":"3","key":"225_CR17","doi-asserted-by":"publisher","first-page":"695","DOI":"10.3390\/jcm9030695","volume":"9","author":"R Mosca","year":"2020","unstructured":"Mosca R, van de Vlekkert D, Campos Y, Fremuth LE, Cadaoas J, Koppaka V, et al. Conventional and Unconventional Therapeutic Strategies for Sialidosis Type I. J Clin Med. 2020;9(3):695.","journal-title":"J Clin Med."},{"issue":"12","key":"225_CR18","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1093\/hmg\/11.12.1455","volume":"11","author":"N de Geest","year":"2002","unstructured":"de Geest N, Bonten E, Mann L, de Sousa-Hitzler J, Hahn C, d\u2019Azzo A. Systemic and neurologic abnormalities distinguish the lysosomal disorders sialidosis and galactosialidosis in mice. Hum Mol Genet. 2002;11(12):1455\u201364.","journal-title":"Hum Mol Genet"},{"issue":"21","key":"225_CR19","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1101\/gad.9.21.2623","volume":"9","author":"XY Zhou","year":"1995","unstructured":"Zhou XY, Morreau H, Rottier R, Davis D, Bonten E, Gillemans N, et al. Mouse model for the lysosomal disorder galactosialidosis and correction of the phenotype with overexpressing erythroid precursor cells. Genes Dev. 1995;9(21):2623\u201334.","journal-title":"Genes Dev"},{"issue":"41","key":"225_CR20","doi-asserted-by":"publisher","first-page":"28430","DOI":"10.1074\/jbc.M109.031419","volume":"284","author":"EJ Bonten","year":"2009","unstructured":"Bonten EJ, Campos Y, Zaitsev V, Nourse A, Waddell B, Lewis W, et al. Heterodimerization of the sialidase NEU1 with the chaperone protective protein\/cathepsin A prevents its premature oligomerization. J Biol Chem. 2009;284(41):28430\u201341.","journal-title":"J Biol Chem"},{"issue":"10","key":"225_CR21","first-page":"1784","volume":"1832","author":"EJ Bonten","year":"2013","unstructured":"Bonten EJ, Yogalingam G, Hu H, Gomero E, van de Vlekkert D, d\u2019Azzo A. Chaperone-mediated gene therapy with recombinant AAV-PPCA in a new mouse model of type I sialidosis. Biochem Biophys Acta. 2013;1832(10):1784\u201392.","journal-title":"Biochem Biophys Acta"}],"container-title":["Acta Epileptologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42494-025-00225-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42494-025-00225-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42494-025-00225-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T17:02:21Z","timestamp":1749056541000},"score":1,"resource":{"primary":{"URL":"https:\/\/aepi.biomedcentral.com\/articles\/10.1186\/s42494-025-00225-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["225"],"URL":"https:\/\/doi.org\/10.1186\/s42494-025-00225-3","relation":{},"ISSN":["2096-9384","2524-4434"],"issn-type":[{"value":"2096-9384","type":"print"},{"value":"2524-4434","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"19 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Medical Ethics Committee of the People\u2019s Hospital of Guangxi Zhuang Autonomous Region (KY-KJT-2023\u2013316) and informed consent was obtained from the family.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication of the case report was obtained from the patients family.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No conflict.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}